Announcements
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
- Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
- Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
More ▼
Key statistics
On Thursday, Ovid Therapeutics Inc (1OT:FRA) closed at 0.635, 3.25% above its 52-week low of 0.615, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.635 |
---|---|
High | 0.635 |
Low | 0.635 |
Bid | 0.635 |
Offer | 0.715 |
Previous close | 0.69 |
Average volume | 276.60 |
---|---|
Shares outstanding | 70.94m |
Free float | 59.68m |
P/E (TTM) | -- |
Market cap | 53.33m USD |
EPS (TTM) | -0.7174 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:04 BST.
More ▼